About
About New Horizon Health Limited
New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2015 and is headquartered in Hangzhou, China.
Visit company website
5 years, 6 months ago
From a valuation standpoint, the stock is 648.8% more expensive than other stocks from the sector with a price to sales ratio of 301.1.
Based on the above factors, New Horizon Health Limited gets an overall score of 0/5.